Y-mAbs Therapeutics | ApexOnco - Clinical Trials news and analysis

x

“I am very impressed - it has become my go-to platform”

Chief Business Officer

US public biotech company

Click here for more information

Deals

6 August 2025

Y-Mabs falls to Serb

The speciality pharma will gain the approved Danyelza and a radiopharma pipeline.

Subscribe to Y-mAbs Therapeutics